Dendrimer nanotherapy targeting of glial dysfunction improves inflammation and neurobehavioral phenotype in adult female Mecp2 ‐heterozygous mouse model of Rett syndrome
Journal of Neurochemistry · 2024
DOI: 10.1111/jnc.15960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, 2024. Verfasst von Elizabeth Smith Khoury und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Rett Syndrome, Methyl-CpG-Binding Protein 2, Neuroglia, Disease Models, Animal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Hartwell Foundation, NICHD NIH HHS.
Abstract (Originalsprache)
Rett syndrome is an X‐linked neurodevelopmental disorder caused by mutation of Mecp2 gene and primarily affects females. Glial cell dysfunction has been implicated in in Rett syndrome (RTT) both in patients and in mouse models of this disorder and can affect synaptogenesis, glial metabolism and inflammation. Here we assessed whether treatment of adult (5–6 months old) symptomatic Mecp2 ‐heterozygous female mice with N ‐acetyl cysteine conjugated to dendrimer (D‐NAC), which is known to target glia and modulate inflammation and oxidative injury, results in improved behavioral phenotype, sleep and glial inflammatory profile. We show that unbiased global metabolomic analysis of the hippocampus and striatum in adult Mecp2 ‐heterozygous mice demonstrates significant differences in lipid metabolism associated with neuroinflammation, providing the rationale for targeting glial inflammation in this model. Our results demonstrate that treatment with D‐NAC (10 mg/kg NAC) once weekly is more efficacious than equivalently dosed free NAC in improving the gross neurobehavioral phenotype in symptomatic Mecp2 ‐heterozygous female mice. We also show that D‐NAC therapy is significantly better than saline in ameliorating several aspects of the abnormal phenotype including paw clench, mobility, fear memory, REM sleep and epileptiform activity burden. Systemic D‐NAC significantly improves microglial proinflammatory cytokine production and is associated with improvements in several aspects of the phenotype including paw clench, mobility, fear memory, and REM sleep, and epileptiform activity burden in comparison to saline‐treated Mecp2 ‐hetereozygous mice. Systemic glial‐targeted delivery of D‐NAC after symptom onset in an older clinically relevant Rett syndrome model shows promise in improving neurobehavioral impairments along with sleep pattern and epileptiform activity burden. These findings argue for the translational value of this approach for treatment of patients with Rett Syndrome. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Center for Nanomedicine, Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Kennedy Krieger Institute, Baltimore, Maryland, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Departments of Pediatrics and Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Departments of Chemical and Biomolecular Engineering, and Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Nirnath Sah, Susanna Scafidi, Sujatha Kannan
Förderung
- NINDS NIH HHS
- Hartwell Foundation
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Khoury, E. S., Patel, R. V., O'Ferrall, C., Fowler, A., Sah, N., Sharma, A., Gupta, S., Scafidi, S., Kurtz, J. S., Olmstead, S. J., Kudchadkar, S. R., Kannan, R. M., Blue, M. E., & Kannan, S. (2024). Dendrimer nanotherapy targeting of glial dysfunction improves inflammation and neurobehavioral phenotype in adult female Mecp2 ‐heterozygous mouse model of Rett syndrome. Journal of Neurochemistry. https://doi.org/10.1111/jnc.15960
Vancouver
Khoury ES, Patel RV, O'Ferrall C, Fowler A, Sah N, Sharma A, et al. Dendrimer nanotherapy targeting of glial dysfunction improves inflammation and neurobehavioral phenotype in adult female Mecp2 ‐heterozygous mouse model of Rett syndrome. Journal of Neurochemistry. 2024. doi:10.1111/jnc.15960
BibTeX
@article{Khoury2024,
author = {Khoury, Elizabeth Smith and Patel, Ruchit V and O'Ferrall, Caroline and Fowler, Amanda and Sah, Nirnath and Sharma, Anjali and Gupta, Siddharth and Scafidi, Susanna and Kurtz, Joshua S and Olmstead, Sarah J and Kudchadkar, Sapna R and Kannan, Rangaramanujam M and Blue, Mary E and Kannan, Sujatha},
title = {Dendrimer nanotherapy targeting of glial dysfunction improves inflammation and neurobehavioral phenotype in adult female Mecp2 ‐heterozygous mouse model of Rett syndrome},
journal = {Journal of Neurochemistry},
year = {2024},
doi = {10.1111/jnc.15960}
}
EUVIMED